Welcome to our dedicated page for InMed Pharmaceuticals Common Shares news (Ticker: $INM), a resource for investors and traders seeking the latest updates and insights on InMed Pharmaceuticals Common Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect InMed Pharmaceuticals Common Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of InMed Pharmaceuticals Common Shares's position in the market.
Rhea-AI Summary
InMed Pharmaceuticals Inc. appoints Dr. David G. Morgan, a leading Alzheimer's expert, to its Scientific Advisory Board, enhancing the development of the INM-901 program for Alzheimer's disease treatment. Dr. Morgan's extensive experience and research contributions in neurodegenerative diseases will bolster InMed's progress in this field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. provides an update on INM-089, a small molecule drug targeting dry Age-Related Macular Degeneration (AMD). The drug demonstrates improved retinal pigment epithelium integrity, neuroprotection, and photoreceptor improvement in preclinical studies. INM-089 acts as a preferential signaling ligand for CB1/CB2 receptors, offering a potential solution for the unmet medical need in treating dry AMD. The company is advancing development activities, including scale-up manufacturing and formulation work, to progress to the next stages of development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. announces positive preclinical data for INM-901 in potential Alzheimer's disease treatment. INM-901 shows preferential signaling agonism for CB1/CB2 receptors and impacts the PPAR signaling pathway, reducing neuroinflammation and improving neuronal function.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) has been granted an additional 180-day compliance period by Nasdaq to meet the minimum bid price requirement for continued listing. The company must achieve a closing bid price of at least $1.00 per share for 10 consecutive business days by September 16, 2024, to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. reports strong financial results for Q2 fiscal year 2024, with a cash position of US$9.5 million, 164% revenue growth in BayMedica subsidiary, and the advancement of two new preclinical programs for Alzheimer's and AMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) appoints Ms. Netta Jagpal as Chief Financial Officer and Corporate Secretary, bringing over 20 years of financial leadership experience in the biotech industry. Ms. Jagpal's background includes roles at D-Wave Systems Inc. (NYSE: QBTS) and Zymeworks Inc. (NYSE: ZYME). Her appointment signifies a strategic move to strengthen InMed's financial capabilities and support its core pharmaceutical drug development business and BayMedica's commercial enterprise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) will participate in the Water Tower Research Fireside Chat Series on January 25, 2024, to discuss its pharmaceutical pipeline in Alzheimer's and ocular, upcoming 2024 milestones, and the role of cannabinoids in Alzheimer's treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. outlines key accomplishments from 2023 and provides strategic priorities for 2024, including the advancement of INM-901 as a treatment for Alzheimer's Disease, the treatment of Age-related Macular Degeneration with INM-089, and seeking partnerships for INM-755 in Dermatology. BayMedica subsidiary continues to focus on revenue growth and market expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) confirms approval of all matters at the annual general meeting of shareholders, including the election of all director nominees. A total of 1,292,647 common shares, representing approximately 38.84% of the Company's issued and outstanding common shares, were represented at the Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) announces the launch of INM-089, a cannabinol (CBN) analog, to investigate its effects in the treatment of Age-related Macular Degeneration (AMD). INM-089 preserved retinal function in an in vivo AMD disease model and improved the thickness of the outer nuclear layer of the retina. The company aims to advance INM-089 to additional in vivo studies as part of the preclinical development program to address the unmet medical need in AMD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.62%
Tags
InMed Pharmaceuticals Inc. Common Shares
Nasdaq:INM
INM Rankings
INM Stock Data
1.62M
4.84M
1.36%
13.29%
0.17%
Research and Development in Biotechnology (except Nanobiotechnology)
Professional, Scientific, and Technical Services
United States of America
VANCOUVER
About INM
inmed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. inmed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.